At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 99 enrolled
Drug / intervention
Rosuvastatin +1 moredrug
Likely dose
Rosuvastatin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of ROsuvastatin Therapy on Peripheral Vasodilator Function, Inflammatory Markers and Pulmonary Function in Patients With StablE Chronic Obstructive Pulmonary Disease
In Brief
A Phase 2 clinical trial evaluating Rosuvastatin and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 99 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate whether rosuvastatin improves measures of endothelial function, decreases measures of inflammation, and improves pulmonary function in patients with stable chronic obstructive pulmonary disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesNorway
CollaboratorsAstraZeneca, Haukeland University Hospital
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJun 2009
Enrollment StartMar 2010
Primary CompletionJan 2014
TodayJul 2026
First PostedJun 29, 2009
Enrollment StartMar 1, 2010
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 17.0 years ago
Interventions
Rosuvastatindrug
10mg tablets, once daily in three months
Placebodrug
1 tablet, once daily in three months